Supreme Court hints skinny labeling may remain viable for generic drugs

At a hearing, Supreme Court justices heard arguments about skinny labeling, a practice used by generic manufacturers to seek approval for a subset of a brand drug's indications.

The justices did not appear to challenge the legal basis of the tactic, suggesting the existing standards under the Hatch-Waxman framework will likely stay unchanged.

If upheld, skinny labeling continues to give generics a pathway to enter markets while avoiding patent infringement claims, preserving a key tool for competition.

The case has drawn attention because a ruling against the practice could close a major route for generic entry, but the current signals point to its survival.